country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-187722

Copy Link Print Information

Enoximone sulfoxide

Name: Enoximone sulfoxide
Brand: MedChemExpress
SKU: HY-187722
Availability: PreOrder

(別名: MDL 19438)

Enoximone sulfoxide (MDL 19438) is the primary sulfoxide metabolite of Enoximone (HY-B1639). Enoximone sulfoxide is also a cardiotonic agent with positive inotropic, positive chronotropic, and vasodilatory activities. Enoximone sulfoxide can be used in the research of congestive heart failure.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号: 83982-78-9
分子式: C₁₂H₁₂N₂O₃S
分子量:264.30

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

Enoximone sulfoxide 構造式

CAS 番号: 83982-78-9

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

体外実験

Enoximone sulfoxide (MDL 19438) (5 μM; incubated for 5-120 min) has the effect of being reduced to Enoximone in the 9000 g supernatant of rat liver and kidney^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

体内実験

Enoximone sulfoxide (3 mg/kg; i.v.; single injection) exhibits positive inotropic activity that is 0.14 times as potent as enoximone but has a 13-fold longer duration of action, plus vasodilator activity, in anaesthetized dogs^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

unspecified (anaesthetized)^[3]
Dosage:

3 mg/kg
Administration:

i.v.; single injection
Result:

Increased cardiac contractile force from baseline, with a duration of inotropic action 13 times longer than that of enoximone.
Demonstrated inotropic activity 0.14 times as potent as enoximone.
Exhibited vasodilator activity.

化学情報

CAS 番号 83982-78-9
分子量 264.30
分子式 C₁₂H₁₂N₂O₃S
SMILES

O=C1NC(C(C2=CC=C(S(C)=O)C=C2)=O)=C(C)N1
別名

MDL 19438
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

プロトコル

All Signal Pathway Related

Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.

純度とドキュメンテーション

取扱説明書 (2659 KB)

参考文献

[1]. Walter B A, et al. An Automated Method for the Determination of Enoximone and Its Major Sulfoxide Metabolite in Plasma Using Robotic Technology–High Performance Liquid Chromatography. Journal of Liquid Chromatography, 1986, 9(14): 3133-3155.

[2]. Uretsky BF, et al. Acute hemodynamic effect of oral MDL 17,043 in severe congestive heart failure. The American journal of cardiology. 1984 Aug 01;54(3):357-62.

[3]. Dage RC, et al. Pharmacology and pharmacokinetics of enoximone. Cardiology. 1990;77 Suppl 3:2-13; discussion 27-33. [Content Brief]

[4]. Ruder MA, et al. Disposition kinetics of orally administered enoximone in patients with moderate to severe heart failure. Journal of clinical pharmacology. 1991 Aug;31(8):702-8.

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ